Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Report Overview
2023
Base Year
2018-2023
Historical Year
2024-2032
Forecast Year
Genetic Cardiomyopathies Market Analysis
Genetic cardiomyopathy is a commonly inherited cardiac illness, affecting approximately 2-5 in a 1000 people. Non-pharmacological treatments like septal myectomy and alcohol septal ablation are frequently used to improve long-term quality of life in patients suffering from genetic cardiomyopathy. Over the years, significant advancements in the non-invasive and pharmacological treatment have been observed.
In 2023, the FDA approved a drug called Mavacamtem, popularly known as Camzyos, as a novel alternative for treating genetic cardiomyopathy. This new class drug, a myosin inhibitor, works by cutting down myosin levels which are present in abundance in the patients.
The genetic cardiomyopathies market value is expected to see a significant hike in the forecast period, with the rising emphasis on using novel techniques to fight the ailment. New study set-ups like induced pluripotent stem cells, three dimensional printing of cells, use of scaffolds and engineered heart tissue, are now being looked upon as a treatment alternative. Moreover, extensive knowledge on mutated proteins, protein quality control, and toxicity has opened new avenue of contemporary techniques like gene editing and repair using CRISPR Cas9, customised drugs and antisense therapies to develop an efficient and accurate treatment for the disease.
With a rising preference for precision medicine, researchers are now combining machine learning guided ECG and imaging analyses to facilitate new targeted drugs. Hence, we can a anticipate a substantial genetic cardiomyopathies market growth in the forecast period.
Genetic Cardiomyopathies Market Report Snapshots
Genetic Cardiomyopathies Market Size
Genetic Cardiomyopathies Market Analysis
Genetic Cardiomyopathies Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Key Questions Answered in the Report
The market attained a value of about USD 1.93 billion in 2023 driven by the rising focus on reducing the number of heart failures associated with genetic cardiomyopathies.
The market is anticipated to grow at a CAGR of 13.3% during the forecast period of 2024-2032, likely to reach a market value of USD 5.93 billion by 2032.
With the arrival of new medicines and techniques to treat genetic cardiomyopathies, the market has seen a substantial growth.
Recently, the FDA approved Mavacamtem, a new drug to treat genetic cardiomyopathy. Moreover, the integration of machine learning in diagnostics to develop precision medicine in the patients are the current market trends.
The major regions of the market include Japan, United States, EU-4 and the United Kingdom.
Major drug types used include anticoagulants, anti-hypertensives, antiarrhytensives, cardiac glycosides and others.
Dilated cardiomyopathy, hypertonic cardiomyopathy, restrictive cardiomyopathy, and others may affect patients.
Different routes of administration for the treatment market include oral and tropical.
The end users in the market include hospitals, clinics, and ambulatory services centres.
Key players involved in the market are Novartis International AG, Merck & Co., Teva Pharmaceuticals, Mylan N.V, Bristo Myers Squibb Company, Boston Scientific Corporation, Sanofi S.A., Becton, Dickinson and Company, Critical Care Diagnostics Inc., and Labcorp.
Purchase Full Report
Datasheet
- Selected Sections, One User
- Printing Not Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Single User License
One User
- All Sections, One User
- One Print Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
Five Users
- All Sections, Five Users
- Five Prints Allowed
- Email Delivery in PDF
- Free Limited Customisation
- Post Sales Analyst Support
50% Discount on Next Update
Corporate License
Unlimited Users
- All Sections, Unlimited Users
- Unlimited Prints Allowed
- Email Delivery in PDF + Excel
- Free Limited Customisation
- Post Sales Analyst Support
- 50% Discount on Next Update
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
Our Offices
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124